AGER and prostate adenocarcinoma: In the validation phase, we found that C1QA, MARCO, TXNDC15, IGFBP3, TNFRSF10C, TRIM5, LAYN, JAM3, RNF43, PPP1R14A, SPINT2, LGALS4, TOR1AIP1, AGER, CILP, CEACAM21, and IL10RB were significantly associated with PRAD risk.